Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
Ramirez AB, Bhat R, Sahay D, De Angelis C, Thangavel H, Hedayatpour S, Dobrolecki LE, Nardone A, Giuliano M, Nagi C, Rimawi M, Osborne CK, Lewis MT, Stilwell JL, Kaldjian EP, Schiff R, Trivedi MV. Ramirez AB, et al. Among authors: rimawi m. BMC Cancer. 2019 Mar 12;19(1):220. doi: 10.1186/s12885-019-5382-1. BMC Cancer. 2019. PMID: 30871481 Free PMC article.
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. Dave B, et al. Among authors: rimawi m. J Clin Oncol. 2011 Jan 10;29(2):166-73. doi: 10.1200/JCO.2009.27.7814. Epub 2010 Dec 6. J Clin Oncol. 2011. PMID: 21135276 Free PMC article.
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.
Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R. Rimawi MF, et al. Clin Cancer Res. 2011 Mar 15;17(6):1351-61. doi: 10.1158/1078-0432.CCR-10-1905. Epub 2010 Dec 7. Clin Cancer Res. 2011. PMID: 21138857 Free PMC article.
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.
Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AV. Litzenburger BC, et al. Among authors: rimawi mf. Clin Cancer Res. 2011 Apr 15;17(8):2314-27. doi: 10.1158/1078-0432.CCR-10-1903. Epub 2010 Dec 22. Clin Cancer Res. 2011. PMID: 21177763 Free PMC article.
116 results